PFNX - Pfenex Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
5.35
+0.13 (+2.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.22
Open5.23
Bid4.00 x 800
Ask8.25 x 900
Day's Range5.17 - 5.62
52 Week Range2.07 - 8.42
Volume353,048
Avg. Volume236,287
Market Cap168.009M
Beta1.78
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)

    Under the agreement, signed in 2007, Pfenex is eligible to receive annual fees, milestone payments, and a tiered royalty based on net sales for all products developed by Merck that use the Pfenex Expression Technology® platform. “This license agreement further illustrates the versatility of the Pfenex platform and its use in products that range from peptides to therapeutic proteins and vaccines,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. Pfenex Inc. is a clinical-stage development and licensing biotechnology company focused on leveraging our Pfēnex Expression Technology® to improve protein therapies for unmet patient needs.

  • GlobeNewswire26 days ago

    Pfenex Set to Join Russell 2000® Index

    SAN DIEGO, June 22, 2018-- Pfenex Inc., a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology ® to improve protein therapies for unmet ...

  • GlobeNewswirelast month

    Pfenex to Present at the JMP Securities 2018 Life Science Conference

    SAN DIEGO, June 14, 2018-- Pfenex Inc. announced today that it will be presenting at the JMP Securities 2018 Life Science Conference in New York City.. President and Chief Executive Officer, Eef Schimmelpennink, ...

  • GlobeNewswirelast month

    Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a Therapeutic Equivalent Candidate to Forteo®

    Pfenex (NYSE American:PFNX) and Alvogen today announced entering into an agreement granting Alvogen exclusive rights to commercialize Pfenex’s lead drug candidate, PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Company’s Forteo®, in the United States. This collaboration aligns the interests and strengths of Pfenex and Alvogen in actions designed to secure regulatory approval and commercializing PF708 in the United States.

  • GlobeNewswire2 months ago

    Pfenex Announces Closing of Public Offering of 7,820,000 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares

    Pfenex Inc. (NYSE American:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today announced the closing of its previously announced underwritten public offering of 7,820,000 shares of its common stock at a price of $5.50 per share, which includes the full exercise by the underwriters of their option to purchase an additional 1,020,000 shares of Pfenex's common stock, pursuant to Pfenex's existing shelf registration statement. Net proceeds to Pfenex from the offering were approximately $39.4 million. Pfenex intends to use the net proceeds from the offering to fund expenses in connection with obtaining regulatory approval and commercialization and launch of PF708, to conduct ongoing research and development, and for general corporate purposes and working capital.

  • GlobeNewswire2 months ago

    Pfenex Announces Pricing of Offering of 6,800,000 Shares of Common Stock

    Pfenex Inc. (NYSE American:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a price of $5.50 per share pursuant to its existing shelf registration statement. Pfenex has granted to the underwriters of the offering a 30-day option to purchase up to an additional 1,020,000 shares of common stock. Barclays Capital Inc. and William Blair & Company, L.L.C. are acting as the joint book-running managers of this offering.

  • GlobeNewswire2 months ago

    Pfenex Announces Offering of Common Stock

    Pfenex Inc. (NYSE American:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Pfenex expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. Pfenex intends to use the net proceeds of the offering to fund expenses in connection with obtaining regulatory approval and commercialization and launch of PF708, to conduct ongoing research and development, and for general corporate purposes and working capital.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PFNX earnings conference call or presentation 10-May-18 8:30pm GMT

    Q1 2018 Pfenex Inc Earnings Call

  • Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018
    PR Newswire2 months ago

    Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018

    - PF708-301 findings show comparable overall profiles of PF708 and Forteo® - No imbalances in severity or incidence of adverse events - Company is on track for submission of NDA in third quarter 2018 - ...

  • PR Newswire2 months ago

    Pfenex Reports First Quarter 2018 Results and Provides Business Update

    SAN DIEGO , May 10, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology ® to ...

  • PR Newswire3 months ago

    Pfenex to Report First Quarter 2018 Results and Provide Business Update on Thursday, May 10th

    SAN DIEGO , April 30, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its first quarter 2018 financial results will be released on Thursday, May 10, 2018 , after the market ...

  • Reuters3 months ago

    BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo

    April 18 (Reuters) - China NT Pharma Group Co Ltd: * PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO® * PFENEX INC - PFENEX ...

  • PR Newswire3 months ago

    Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo®

    SAN DIEGO and HONG KONG, April 18, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX) and China NT Pharma Group Company Limited (NT Pharma) (1011.HK) today announced an agreement under which Pfenex granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Company's Forteo®, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand. In accordance with the agreement, Pfenex received a payment of $2.5 million upon signing of the agreement and may be eligible to receive additional payments of up to $22.5 million based on the achievement of certain development, regulatory, and sales-related milestones.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of PFNX earnings conference call or presentation 15-Mar-18 8:30pm GMT

    Q4 2017 Pfenex Inc Earnings Call

  • PR Newswire4 months ago

    Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update

    SAN DIEGO , March 15, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology ® ...

  • ACCESSWIRE4 months ago

    Pfenex, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Pfenex, Inc. (NYSE American: PFNX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern Time. ...

  • One Thing To Consider Before Buying Pfenex Inc (NYSEMKT:PFNX)
    Simply Wall St.4 months ago

    One Thing To Consider Before Buying Pfenex Inc (NYSEMKT:PFNX)

    If you are looking to invest in Pfenex Inc’s (AMEX:PFNX), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • PR Newswire4 months ago

    Pfenex Inc. to Present at Oppenheimer's 28th Annual Healthcare Conference

    SAN DIEGO , March 13, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that the company will present at Oppenheimer's 28th Annual Healthcare Conference in New York City . President ...

  • PR Newswire4 months ago

    Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018

    SAN DIEGO , March 8, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its fourth quarter and full year 2017 financial results will be released on Thursday, March 15, 2018 , after ...

  • PR Newswire5 months ago

    Pfenex Inc. to Present at Barclay's 2018 Global Healthcare Conference

    SAN DIEGO , Feb. 27, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that the company will present at Barclay's 2018 Global Healthcare Conference in Miami Beach, Florida . President ...

  • PR Newswire6 months ago

    Pfenex Names Susan A. Knudson as Chief Financial Officer

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) today announced the appointment of Susan A. Knudson as Chief Financial Officer, effective February 1, 2018. "After a thorough search, we are pleased to welcome Susan to the Pfenex team as our Chief Financial Officer," said Eef Schimmelpennink, Chief Executive Officer of Pfenex. Ms. Knudson most recently served as the Chief Financial Officer of Neothetics, Inc., a specialty pharmaceutical company, where she led the company's strategic and corporate finance activities.  Prior to her role at Neothetics, Ms. Knudson served as Senior Director of Finance and Administration at Avera Pharmaceuticals, where she drove financing strategy, and was an integral part of the business development team interacting with multinational pharmaceutical companies.

  • PR Newswire7 months ago

    Pfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz Pharmaceuticals

    SAN DIEGO, Dec. 19, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX) today announced the amendment of the 2016 agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. Under the amended agreement, Pfenex will be eligible to receive an additional $43.5 million in amendment fee and development milestone payments as compared to the 2016 agreement, increasing the total value of upfront, option and amendment fee payments and potential payments for the achievement of development, regulatory and sales-related milestones associated with the collaboration to an aggregate of $224.5 million.  Pfenex will also continue to be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration, at rates reduced from those under the 2016 agreement.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of PFNX earnings conference call or presentation 9-Nov-17 9:30pm GMT

    Q3 2017 Pfenex Inc Earnings Call